COLO B Coloplast A/S Class B

Coloplast launches Saffron™ Fixation System for Prolapse Repair

Coloplast launches Saffron™ Fixation System for Prolapse Repair

Coloplast is introducing the Saffron™ Fixation System designed for ease and reliability during pelvic floor reconstruction for women who suffer from pelvic organ prolapse (POP).

“Our goal was to create an easy-to-use fixation tool that enables physicians to consistently attach sutures to the ligaments of the pelvic floor. We want to invest in products that help surgeons treat women suffering from pelvic floor issues, and Saffron does just that,” says Steve Blum, President of Interventional Urology at Coloplast.





Consistent, reliable deployment; ease of navigation; and more choice

The Saffron™ Fixation System is indicated for attaching sutures to ligaments of the pelvic floor. The system allows for surgeons to use their choice of sutures and needles for POP repair and pairs ease of navigation with consistent, reliable anchor deployment for a secure fixation. It is intuitive and easy to use, and surgeons report high satisfaction1.

“With Saffron, I can easily navigate through the surgical space to access the fixation site, and the unique curve enables perpendicular alignment on the ligament. The tool fits in my hand, is easy to deploy, and the anchor is smooth and secure for my prolapse repairs,” says Dr. Heather van Raalte, medical director of Princeton Urogynecology and the Pelvic Wellness Center in Princeton, NJ. 

Saffron will be commercially available in the US market in the fall of 2022. It joins the existing portfolio of products that Coloplast provides for pelvic floor reconstruction in women.   

For more information, please visit About Coloplast

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology, and Voice and Respiratory Care. We operate globally and employ about 14,000 employees.

CONTACTS

Peter Mønster

Sr. Media Relations Manager, Corporate Communications



Aleksandra Dimovska

Director, Investor Relations



1Data on file



 

 

Attachments



EN
06/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast annoncerer ændringer i ledelsesteamet

Coloplast annoncerer ændringer i ledelsesteamet Coloplast offentliggør i dag ændringer til ledelsesteamet (ELT). Ændringerne omhandler Coloplasts urologiforretning og virksomhedens globale funktion for People & Culture. Leder af People & Culture, Dorthe Rønnau, har besluttet at forlade Coloplast for at starte et nyt kapitel i sin karriere. Dorthe Rønnau har haft forskellige roller på tværs af Coloplast-koncernen i næsten tre årtier. ”Coloplast har haft stor glæde af Dorthes værdier, integritet og stærke lederevner i hendes roller i Global Operations, Atos og People & Culture, og den øvers...

 PRESS RELEASE

Coloplast announces changes to Executive Leadership Team

Coloplast announces changes to Executive Leadership Team Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group. “Dorthe’s values, integrity and strong leadership skills have benefitted the company across her roles in Global Op...

 PRESS RELEASE

Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025

Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025 I dag, den 4. december 2025, afholdt Coloplast A/S sin ordinære generalforsamling, hvor følgende beslutninger blev vedtaget: Årsrapporten for regnskabsåret 2024/25 blev godkendt.Forslag om udbetaling af udbytte for året på 18,00 kr. pr. aktie à nominelt 1 kr. blev godkendt. I tillæg til de 5,00 kr. pr. aktie à nominelt 1 kr., der blev udbetalt i forbindelse med Coloplast A/S’ halvårsresultat, bliver det samlede udbytte for regnskabsåret 2024/25 således 23,00 kr. pr. aktie à nominelt 1 kr.Vederlagsrapporten for regnskabsåre...

 PRESS RELEASE

Coloplast A/S - Decisions at the Annual General Meeting 2025

Coloplast A/S - Decisions at the Annual General Meeting 2025 Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved.Distribution of year-end dividend of DKK 18.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.The remuneratio...

 PRESS RELEASE

Coloplast A/S - Notice of Annual General Meeting 2025

Coloplast A/S - Notice of Annual General Meeting 2025 Notice of Annual General Meeting 2025 The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the Annual General Meeting is enclosed.   For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. Kristine Husted MunkSr. Director, Investor RelationsTel. / Email: Simone Dyrby HelvindSr. Manager, Inve...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch